Recent Company News

• 07:34 AM ET Aug 07, 2026
  

  Healthcare, tech and financials the best performers; energy, utilities and autos the big laggards:

• 02:03 AM ET Aug 07, 2026
  

  Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years (DKK 175.00, 0.00)

• 09:02 AM ET Jul 13, 2026
  

  Bavarian Nordic notes Chikungunya vaccine submitted for regulatory approval in Brazil (DKK 183.30, -0.20)

• 03:58 AM ET Jul 13, 2026
  

  Bavarian Nordic A/S completes share buyback initiated on 2-Jun (DKK 182.20, -1.30)

• 01:43 AM ET Jul 09, 2026
  

  Bavarian Nordic A/S resumed buy at Nordea; prior rating was hold (DKK 187.70, 0.00)

• 01:30 AM ET Jun 29, 2026
  

  Bavarian Nordic receives Health Canada approval for Chikungunya vaccine (DKK 179.00, 0.00)

• 08:51 AM ET Jun 26, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:34 AM ET Jun 26, 2026
  

  EMA CHMP publishes summary of opinions for June 2026 meeting

• 07:08 AM ET Jun 26, 2026
  

  EU's CHMP adopted a positive opinion recommending change to terms of marketing authorisation for medicinal product Imvanex (DKK 174.90, -3.30)

• 06:54 AM ET Jun 09, 2026
  

  Bavarian Nordic secures additional government contract for the supply of smallpox/mpox vaccine; contract valued at over DKK700M (DKK 181.70, +3.40)